摘要
为进一步探讨参松养心胶囊的临床安全性,对其在治疗心律失常上的疗效与比索洛尔(康忻)的疗效进行了比较.将100例心律失常患者随机分为2组:治疗组为50例,参松养心胶囊口服,每次4粒,每日3次;对照组50例,比索洛尔口服,每次5mg,每日1次.疗程定为3个月,观察结果是:治疗组与对照组在治疗心律失常上临床疗效无统计学差异(P>0.05);而在不良反应方面有统计学差异(P<0.05).可见参松养心胶囊在治疗心律失常上与比索洛尔相比具有安全有效的优势.
Curative effects of Shensongyangxin capsule and bisoprolol on arrhythmia were compared. One hundred patients with arrhythmia were divided randomly into 2 groups. Fifty patients received oral Shensongyangxin capsules （4 capsules each time, 3 times daily）; fifty other patients received oral bisoprolol （5 mg each time, once a daly）. This treatment protocol lasted for 3 months. The two groups showed no difference in curative effect （P〉0. 05）. But in terms of side effects, significant differences existed between the two groups （P〈0. 05）. Shensongyangxin capsule is superior than bisoprolol in arrhythmia treatment in terms of drug safety.
出处
《北京师范大学学报（自然科学版）》
CAS
CSCD
北大核心
2009年第4期436-437,共2页
Journal of Beijing Normal University(Natural Science)
